What is BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price today?

BridgeBio Oncology Therapeutics, Inc. (BBOT) currently trades at $8.41 per share. The stock has a market capitalization of $702.69M and a P/E ratio of —x.

Is BBOT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, BridgeBio Oncology Therapeutics, Inc. has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is —.

Is BridgeBio Oncology Therapeutics, Inc. financially healthy?

BridgeBio Oncology Therapeutics, Inc.'s Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of — places it in the —.

BBOT

BridgeBio Oncology Therapeutics, Inc.

NASDAQ: BBOT · HEALTHCARE · BIOTECHNOLOGY

$8.41

+4.34% today

Updated 2026-04-30

Market cap

$702.69M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.30

Dividend yield

—

52W range

$8 – $15

Volume

0.3M

Market cap

$702.69M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.30

Dividend yield

—

52W range

$8 – $15

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.8

Quality

B+

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$25.38

+201.78%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Thin margins at 0.00%

- Negative free cash flow $-42.55M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	—	$0.00	$0.00	$0.00	$0.00
Net income	$-3520.00	$-64.70M	$-74.28M	$-134.04M	$-38.80M
EPS	—	—	—	—	$-4.30
Free cash flow	—	$-52.49M	$-812820.00	$-114.50M	$-42.55M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BBOT	$702.69M	31	4.3	3.0	5.0	7.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

BridgeBio Oncology Therapeutics, Inc. trades at $8.41. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score.

Frequently asked questions

What is BridgeBio Oncology Therapeutics, Inc.'s stock price?

BridgeBio Oncology Therapeutics, Inc. (BBOT) trades at $8.41.

Is BridgeBio Oncology Therapeutics, Inc. overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of BridgeBio Oncology Therapeutics, Inc. (BBOT)?

The analyst target price is $25.38, representing +201.8% upside from the current price of $8.41.

Piotroski F-Score?

4/9 — moderate financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-48.20%

Beta0.51

50D MA$9.49

200D MA$10.93

Shares out0.08B

Float0.03B

Short ratio—

Avg volume0.3M

Performance

1 week-4.21%

1 month-6.87%

3 months-28.24%

YTD-32.83%

1 year—

3 years—

5 years—

Compare

BBOT vs LLY →BBOT vs JNJ →BBOT vs ABBV →Stock screener →